▷ Enable Injections Announces $215 Million Funding


27.01.2022 – 17:13

Enable Injections, Inc.

Cincinnati (ots/PRNewswire)

The new financing provides significant financial flexibility to drive growth, benefiting patients, providers and pharmaceutical partners worldwide.

Enable Injections, Inc. (“Enable”), a company that designs and manufactures the enFuse® platform of wearable research drug delivery systems, is pleased to announce a $215 million Series C financing. Magnetar Capital (” Magnetar”) led the financing along with new institutional investments from GCM Grosvenor, Squarepoint Capital, Woody Creek Capital Partners and other investors. Enable continued to receive significant support from existing investors including Cincinnati Children’s Hospital Medical Center, CincyTech, Cintrifuse and the Ohio Innovation Fund.

Enable Injections’ EnFuse® is an innovative technology for subcutaneous delivery of large volumes (up to 50mL) of drugs for a variety of therapies and diseases, offering patients and physicians a safe, convenient and cost-effective alternative to intravenous administration. With improved flexibility for patients and healthcare providers, enFuse aims to increase the efficiency of healthcare providers, minimize patient burden in the clinic and reduce healthcare costs, with the aim of benefiting patients and healthcare providers worldwide.

“Enable Injections has seen a dramatic increase in demand for enFuse’s high-volume drug delivery technology. The Magnetar funding will help enFuse redefine IV drug delivery by significantly expanding our development and commercialization efforts. This will allow us to reach even more patients who rely on IV medications and we believe it will make a significant difference in their lives,” said Mike Hooven, President and CEO of Enable Injections We are pleased to be working with Magnetar to expand the enFuse platform globally and realize our shared vision of creating the next generation of connections between patients and healthcare providers through an enhanced healthcare experience to support injection administration.”

“This funding will provide us with additional resources to onboard important new pharma partner programs and to accelerate our commercialization programs and platforms with existing pharma partners,” said Tim Flaherty, EVP and CFO of Enable Injections. “Enable is with Magnetar as a strategic partner and its thoughtful approach to healthcare investing, a stronger company

UBS Securities LLC acted as the exclusive placement agent for Enable Injections in connection with this financing.

About Enable Injections:

Based in Cincinnati, Enable Injections designs and manufactures subcutaneous drug delivery systems to improve the patient experience, achieve better outcomes, and increase the value and profitability of the healthcare system. Enable’s enFuse® body-worn drug delivery platform utilizes standard canister closure systems to deliver bulk pharmaceutical and biological therapeutics. For more information please visit www.enableinjections.com.

About Magnetar Capital:

Founded in 2005, Magnetar is a multi-strategy alternative investment manager with approximately $13.5 billion in assets under management (as of September 30, 2021). Magnetar seeks stable, risk-adjusted returns by opportunistically employing a wide range of alternative credit and fixed income, energy and infrastructure, and systematic investment strategies. Magnetar invests across geographies and corporate structures, in both public and private markets, taking advantage of rigorous fundamental and quantitative analysis. The company is based in Evanston, Illinois with additional offices in London and Houston. For more information, see www.magnetar.com.

Photo – https://mma.prnewswire.com/media/1734916/Enable_Injections_enFuse.jpg

Logo – https://mma.prnewswire.com/media/962405/Enable_Injections_Logo.jpg

Press contact:

Jennifer Estep,
Enable Injections,
513-326-2800,
[email protected]

Original content from: Enable Injections, Inc., transmitted by news aktuell


www.presseportal.de

Leave a Reply

Your email address will not be published.